Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BL-B01D1 Combination Therapy in Metastatic Castration-resistant Prostate Cancer
NCT07641855Phase 3Not yet recruiting
- Sponsor
- Biokin Pharmaceutical
- Start
- Sep 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
A Phase 3 trial of izalontamab brengitecan in castration-resistant prostate cancer (CRPC), sponsored by Biokin Pharmaceutical. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
izalontamab brengitecan
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT07641855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07641855.